Cadrenal Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) on June 3, 2026, reporting events occurring on May 28, 2026. The Company is an emerging growth company incorporated in Delaware, headquartered in Ponte Vedra, Florida.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on executive compensation and personnel changes.
Material Changes
- Executive Departure: Matthew K. Szot transitioned from the role of Chief Financial Officer (CFO) effective May 28, 2026, by mutual agreement.
- Interim Appointment: Quang X. Pham, the Company's Chief Executive Officer, was appointed as interim CFO and interim Principal Accounting Officer effective immediately following Mr. Szot's departure.
- Severance Agreement: On June 3, 2026, the Company entered into a separation and release agreement with Mr. Szot.
Guidance, Outlook, and Unusual Items
The filing contains no forward-looking guidance, market outlook, or discussion of operational risks beyond the executive transition. The primary unusual item is the severance package details:
- Severance Payment: A gross amount of $365,806.00, payable in four equal installments of $91,451.50 starting after the revocation period, with subsequent payments on July 3, August 3, and September 3, 2026.
- Target Bonus: Payment of the 2026 annual target cash bonus totaling $237,903.00, payable in two equal installments of $118,951.50.
- Equity Acceleration: Accelerated vesting of all outstanding stock options issued to Mr. Szot, which remain exercisable until their original expiration dates.
- Conditions: The agreement is subject to a seven-day revocation period and includes a general release of claims and a non-disparagement clause.
Investor Verification Checklist
- Verify the status of the search for a permanent Chief Financial Officer replacement.
- Confirm the impact of the interim CFO arrangement on the Company's financial reporting timeline and internal controls.
- Review the attached Exhibit 10.1 (Severance and Release Letter Agreement) for full legal terms and conditions.
- Monitor future filings for any additional executive departures or changes in the Board of Directors.